DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

Similar documents
DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364

MDwise Self-Administered Codes for Medical

Medicare Part B Covered Medications

Drug Name Tier Drug Name Tier

The following are J Code requirements

Injections Requiring Prior Authorization

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

MEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT

Subject: Palonosetron Hydrochloride (Aloxi )

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Modular Program Report

External Infusion Pumps

Table III: 2019 Medicare Drug Fee Schedule* CY st Quarter Average Sales Price (ASP) Data Plus 6 Percent

MASCC Guidelines for Antiemetic control: An update

A9542 A9543 A9545 A9699 J0120 J0128 J0129 J0130

Drug Use Evaluation: Physician Administered Drugs (PADs)

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Highmark List of Procedure Codes Requiring NDC Effective 12/01/2017

Guideline Update on Antiemetics

Medicare Part C Medical Coverage Policy

MEDICAL MANAGEMENT POLICY

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

Immune Globulin. Prior Authorization

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

High Risk Medications

Injectables/Medications Administered Under the Medical Benefit Authorization NOT Required List Effective 04/01/2017

Guidelines for the Use of Anti-Emetics with Chemotherapy

Drug Class Prior Authorization Criteria Immune Globulins

See Important Reminder at the end of this policy for important regulatory and legal information.

Cigna Drug and Biologic Coverage Policy

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Medicare Part C Medical Coverage Policy

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

LCD for Nebulizers (L27226)

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

LCD for Nebulizers (L11488)

Intravenous Immune Globulin (IVIg)

Cost-Motivated Treatment Changes in Medicare Part B:

Managements of Chemotherpay Induded Nausea and Vomiting

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

See Important Reminder at the end of this policy for important regulatory and legal information.

Welcome. Coding uidelines Coding Guidelines Coding. Coding Guidelines Coding Guidelines. Contact Us. Edition #1 March 2018

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Generic (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists

NOTICES DEPARTMENT OF HEALTH

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

See Important Reminder at the end of this policy for important regulatory and legal information.

Part B payment for drugs in Medicare 0

Measure Abbreviation: PONV 01 (MIPS 430)

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

Northern Cancer Alliance

CURRENT DRUG SHORTAGES (through February 22, 2013) CURRENT & ONGOING SHORTAGES CRITICAL SHORTAGES

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical

Billing & Coding Guide

Antiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue

Product Name Strength Dosage Form Therapeutic Area Dossier Status. Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000

Corporate Medical Policy

TennCare Program TN MAC Price Change List As of: 03/30/2017

Clinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients

IHCP banner page INDIANA HEALTH COVERAGE PROGRAMS BR FEBRUARY 16, 2016

Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

CPT Service Description Effective Date


A CMS Program Safeguard Contractor. The following list identifies changes to level II Healthcare Common Procedure Coding System (HCPCS) for 2008.

RITUXAN (rituximab and hyaluronidase human)

MEDICAL NECESSITY GUIDELINE

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

See Important Reminder at the end of this policy for important regulatory and legal information.

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Our mission is better health care outcomes.

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting

See Important Reminder at the end of this policy for important regulatory and legal information.

ADULT Updated: September 4, 2018

See Important Reminder at the end of this policy for important regulatory and legal information.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue

Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Part B payment for drugs in Medicare 0

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

Measure Abbreviation: PONV 01 (MIPS 430)

Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients

Emetogenicity level 1. Emetogenicity level 2

Modular Program Report

To help doctors give their patients the best possible care, the American

Transcription:

G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $8.071 J0288 INJECTION, AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX 10 MG TBD* J0289 INJECTION, AMPHOTERICIN B LIPOSOME 10 MG $22.193 J0895 INJECTION, DEFEROXAMINE MESYLATE 500 MG $9.615 J1170 INJECTION, HYDROMORPHONE UP TO 4 MG $2.708 J1250 INJECTION, DOBUTAMINE HYDROCHLORIDE 250 MG $7.319 J1265 INJECTION, DOPAMINE HCL 40 MG $0.816 J1325 INJECTION, EPOPROSTENOL 0.5 MG $16.155 J1455 INJECTION, FOSCARNET SODIUM 1000 MG $82.268 J1459 INJECTION, IMMUNE GLOBULIN (PRIVIGEN), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID) 500 MG $40.318 J1555 INJECTION, IMMUNE GLOBULIN (CUVITRU) 100 MG $13.605 J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $70.516 J1557 INJECTION, IMMUNE GLOBULIN, (GAMMAPLEX), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID) 500 MG $45.890 J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $10.112 J1561 J1561JB INJECTION, IMMUNE GLOBULIN, (GAMUNEX- C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID) INJECTION, IMMUNE GLOBULIN, (GAMUNEX- C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID) [JB modifier indicates drug being administered subcutaneously] 500 MG $40.114 500 MG Same as J1561** J1562 INJECTION, IMMUNE GLOBULIN (VIVAGLOBIN) 100 MG TBD* INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, J1566 LYOPHILIZED (E.G. POWDER), NOT OTHERWISE 500 MG $43.110 SPECIFIED J1568 INJECTION, IMMUNE GLOBULIN, (OCTAGAM), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID) 500 MG $35.471 J1569 INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID) 500 MG $42.227 J1569JB INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID) [JB modifier indicates drug being administered subcutaneously] 500 MG Same as J1569** J1570 INJECTION, GANCICLOVIR SODIUM 500 MG $56.252 INJECTION, IMMUNE GLOBULIN, J1572 (FLEBOGAMMA/FLEBOGAMMA DIF), INTRAVENOUS, NON- 500 MG $34.397 LYOPHILIZED (E.G. LIQUID) J1575 INJECTION, IMMUNE GLOBULIN/HYALURONIDASE, (HYQVIA) 100 MG $14.178 J1817 INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) 50 UNITS $10.947 J2175 INJECTION, MEPERIDINE HYDROCHLORIDE 100 MG $4.053 J2260 INJECTION, MILRINONE LACTATE 5 MG $1.403 J2270 INJECTION, MORPHINE SULFATE UP TO 10 MG $2.774 J2274 INJECTION, MORPHINE SULFATE, PRESERVATIVE-FREE FOR EPIDURAL OR INTRATHECAL USE 10 MG $16.416 Copyright 2018 CGS Administrators, LLC. Page 1 of 6 12/29/2018

J2278 INJECTION, ZICONOTIDE 1 MCG $7.729 J2545 PENTAMIDINE ISETHIONATE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, 300 MG $109.689 J2920 INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE UP TO 40 MG $4.872 J2930 INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE UP TO 125 MG $6.928 J3010 INJECTION, FENTANYL CITRATE 0.1 MG $0.829 J3285 INJECTION, TREPROSTINIL 1 MG $66.125 J7340 CARBIDOPA 5 MG/LEVODOPA 20 MG ENTERAL SUSPENSION 100 ML $213.950 J7500 AZATHIOPRINE, ORAL 50 MG $0.886 J7501 AZATHIOPRINE, PARENTERAL 100 MG TBD* J7502 CYCLOSPORINE, ORAL 100 MG $2.449 J7503 TACROLIMUS, EXTENDED RELEASE, (ENVARSUS XR), 0.25 MG ORAL $1.287 J7504 LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE 250 MG GLOBULIN, EQUINE, PARENTERAL $2,066.117 J7507 TACROLIMUS, IMMEDIATE RELEASE, ORAL 1 MG $0.581 J7508 TACROLIMUS, EXTENDED RELEASE, ORAL 0.1 MG $0.469 J7509 METHYLPREDNISOLONE, ORAL 4 MG $0.369 J7510 PREDNISOLONE, ORAL 5 MG $0.056 J7511 LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE 25 MG GLOBULIN, RABBIT, PARENTERAL $731.324 J7512 PREDNISONE, IMMEDIATE RELEASE OR DELAYED 1 MG RELEASE, ORAL $0.018 J7515 CYCLOSPORINE, ORAL 25 MG $0.720 J7516 CYCLOSPORINE, PARENTERAL 250 MG $48.893 J7517 MYCOPHENOLATE MOFETIL, ORAL 250 MG $1.026 J7518 MYCOPHENOLIC ACID, ORAL 180 MG $3.356 J7520 SIROLIMUS, ORAL 1 MG $7.226 J7525 TACROLIMUS, PARENTERAL 5 MG $206.014 J7527 EVEROLIMUS, ORAL 0.25 MG $8.621 J7605KO ARFORMOTEROL, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, 15 MCG $9.688 J7606KO FORMOTEROL FUMARATE, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, 20 MCG $11.316 J7608KO ACETYLCYSTEINE, INHALATION SOLUTION, FDA- APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 GM $5.073 J7611 ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1 MG THROUGH DME, CONCENTRATED FORM $0.150 J7612 LEVALBUTEROL, INHALATION SOLUTION, FDA- APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, CONCENTRATED FORM 0.5 MG $0.215 Copyright 2018 CGS Administrators, LLC. Page 2 of 6 12/29/2018

ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED J7613KO FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1 MG THROUGH DME, UNIT DOSE $0.043 LEVALBUTEROL, INHALATION SOLUTION, FDA- J7614KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 0.5 MG ADMINISTERED THROUGH DME, UNIT DOSE $0.061 ALBUTEROL, UP TO 2.5 MG AND IPRATROPIUM BROMIDE, J7620 UP TO 0.5 MG, FDA-APPROVED FINAL PRODUCT, NON- 1 UNIT COMPOUNDED, ADMINISTERED THROUGH DME $0.136 BUDESONIDE, INHALATION SOLUTION, FDA-APPROVED J7626KO FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED UP TO 0.5 MG THROUGH DME, UNIT DOSE FORM $2.237 CROMOLYN SODIUM, INHALATION SOLUTION, FDA- J7631KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 10 MG $5.583 DORNASE ALPHA, INHALATION SOLUTION, FDA- J7639KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 MG $47.790 IPRATROPIUM BROMIDE, INHALATION SOLUTION, FDA- J7644KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 MG $0.206 METAPROTERENOL SULFATE, INHALATION SOLUTION, J7669KO FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, 10 MG TBD* TOBRAMYCIN, INHALATION SOLUTION, FDA-APPROVED J7682KO FINAL PRODUCT, NON-COMPOUNDED, UNIT DOSE 300 MG FORM, ADMINISTERED THROUGH DME $39.672 TREPROSTINIL, INHALATION SOLUTION, FDA-APPROVED J7686KO FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1.74 MG THROUGH DME, UNIT DOSE FORM $584.325 J8501 APREPITANT, ORAL 5 MG $5.802 J8520 CAPECITABINE, ORAL 150 MG $1.155 J8521 CAPECITABINE, ORAL 500 MG $3.674 J8530 CYCLOPHOSPHAMIDE; ORAL 25 MG $4.540 J8540 DEXAMETHASONE, ORAL 0.25 MG $0.062 J8610 METHOTREXATE; ORAL 2.5 MG $0.384 J8650 NABILONE, ORAL 1 MG $41.556 J8655 NETUPITANT AND PALONOSETRON, ORAL 300 MG and 0.5 MG $282.827 J8670 ROLAPITANT, ORAL 1 MG $1.307 J9000 INJECTION, DOXORUBICIN HYDROCHLORIDE 10 MG $3.063 J9039 INJECTION, BLINATUMOMAB 1 MCG $110.153 J9040 INJECTION, BLEOMYCIN SULFATE 15 UNITS $28.775 J9065 INJECTION, CLADRIBINE 1 MG $21.876 J9100 INJECTION, CYTARABINE 100 MG $0.766 J9190 INJECTION, FLUOROURACIL 500 MG $1.791 J9200 INJECTION, FLOXURIDINE 500 MG $75.589 J9208 INJECTION, IFOSFAMIDE 1 GM $25.447 J9355 INJECTION, TRASTUZUMAB 10 MG $106.995 J9360 INJECTION,VINBLASTINE SULFATE 1 MG $3.687 J9370 VINCRISTINE SULFATE 1 MG $4.946 Copyright 2018 CGS Administrators, LLC. Page 3 of 6 12/29/2018

Q0162 ONDANSETRON, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT THE TIME OF CHEMOTHERAPY TREATMENT, NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN 1 MG $0.026 Q0163 DIPHENHYDRAMINE HYDROCHLORIDE, ORAL, FDA TO EXCEED A 48 HOUR DOSAGE REGIMEN 50 MG $0.262 Q0164 PROCHLORPERAZINE MALEATE, ORAL, FDA APPROVED A 48 HOUR DOSAGE REGIMEN 5MG $0.035 Q0166 Q0167 GRANISETRON HYDROCHLORIDE, ORAL, FDA TO EXCEED A 24 HOUR DOSAGE REGIMEN DRONABINOL, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN 1 MG 2.5 MG $2.871 $1.166 Q0169 PROMETHAZINE HYDROCHLORIDE, ORAL, FDA TO EXCEED A 48 HOUR DOSAGE REGIMEN 12.5 MG $0.015 Q0173 TRIMETHOBENZAMIDE HYDROCHLORIDE, ORAL, FDA TO EXCEED A 48 HOUR DOSAGE REGIMEN 250 MG TBD* Q0174 THIETHYLPERAZINE MALEATE, ORAL, FDA APPROVED A 48 HOUR DOSAGE REGIMEN 10 MG TBD* Copyright 2018 CGS Administrators, LLC. Page 4 of 6 12/29/2018

Q0175 Q0177 Q0180 Q0510 Q0511 Q0512 PERPHENAZINE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN HYDROXYZINE PAMOATE, ORAL, FDA APPROVED A 48 HOUR DOSAGE REGIMEN DOLASETRON MESYLATE, ORAL, FDA APPROVED A 24 HOUR DOSAGE REGIMEN PHARMACY SUPPLY FEE FOR INITIAL IMMUNOSUPPRESSIVE DRUG(S), FIRST MONTH FOLLOWING TRANSPLANT PHARMACY SUPPLY FEE FOR ORAL ANTI-CANCER, ORAL ANTI-EMETIC OR IMMUNOSUPPRESSIVE DRUG(S); FOR THE FIRST PRESCRIPTION IN A 30-DAY PERIOD PHARMACY SUPPLY FEE FOR ORAL ANTI-CANCER, ORAL ANTI-EMETIC OR IMMUNOSUPPRESSIVE DRUG(S); FOR A SUBSEQUENT PRESCRIPTION IN A 30-DAY PERIOD Copyright 2018 CGS Administrators, LLC. Page 5 of 6 12/29/2018 4 MG 25 MG $1.350 $0.144 100 MG $101.236 $50.000 $24.000 $16.000 Q0513 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); PER 30 DAYS $33.000 Q0514 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); PER 90 DAYS $66.000 Q4074 ILOPORST, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED UP TO 20 MCG $141.833 THROUGH DME, UNIT DOSE FORM NDC number BUSULFAN, ORAL 2 MG $24.128 NDC number CAPECITABINE, ORAL 150 MG $1.155 NDC number CAPECITABINE, ORAL 500 MG $3.674 NDC number CYCLOPHOSPHAMIDE, ORAL 25 MG $4.540 NDC number CYCLOPHOSPHAMIDE, ORAL 50 MG $9.080 NDC number ETOPOSIDE, ORAL 50 MG $75.761 NDC number FLUDARABINE PHOSPHATE, ORAL 10 MG TBD* NDC number MELPHALAN, ORAL 2 MG $12.000 NDC number METHOTREXATE, ORAL 2.5 MG $0.384 NDC number METHOTREXATE, ORAL 5 MG $0.768 NDC number METHOTREXATE, ORAL 7.5 MG $1.152 NDC number METHOTREXATE, ORAL 10 MG $1.536 NDC number METHOTREXATE, ORAL 15 MG $2.304 NDC number TEMOZOLOMIDE, ORAL 5 MG $0.867 NDC number TEMOZOLOMIDE, ORAL 20 MG $3.468 NDC number TEMOZOLOMIDE, ORAL 100 MG $17.340 NDC number TEMOZOLOMIDE, ORAL 250 MG $43.350

NDC number TOPOTECAN, ORAL 0.25 MG $103.554 *To Be Developed (TBD) indicates the claim will be developed for an invoice on the drug billed. ** Effective January 1, 2017, the HCPCS code with the JB modifier no longer has a different fee than the HCPCS code without the JB modifier. Copyright 2018 CGS Administrators, LLC. Page 6 of 6 12/29/2018